Share-based Payment Arrangement, Noncash Expense of ALPINE IMMUNE SCIENCES, INC. from 31 Dec 2013 to 31 Mar 2024
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount of noncash expense for share-based payment arrangement.
- Summary
-
ALPINE IMMUNE SCIENCES, INC. quarterly and annual Share-based Payment Arrangement, Noncash Expense in USD history and change rate from 31 Dec 2013 to 31 Mar 2024.
- ALPINE IMMUNE SCIENCES, INC. Share-based Payment Arrangement, Noncash Expense for the quarter ending 31 Mar 2024 was $3,989,000, a 56% increase year-over-year.
- ALPINE IMMUNE SCIENCES, INC. annual Share-based Payment Arrangement, Noncash Expense for 2023 was $10,630,000, a 10% increase from 2022.
- ALPINE IMMUNE SCIENCES, INC. annual Share-based Payment Arrangement, Noncash Expense for 2022 was $9,648,000, a 55% increase from 2021.
- ALPINE IMMUNE SCIENCES, INC. annual Share-based Payment Arrangement, Noncash Expense for 2021 was $6,240,000, a 51% increase from 2020.
- Source SEC data
- View on sec.gov
Share-based Payment Arrangement, Noncash Expense, Quarterly (USD)
Share-based Payment Arrangement, Noncash Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Noncash Expense, Annual (USD)
Share-based Payment Arrangement, Noncash Expense, YoY Annual Change (%)
ALPINE IMMUNE SCIENCES, INC. Quarterly Share-based Payment Arrangement, Noncash Expense (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2024 | $3,989,000 | +$1,437,000 | +56% | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 09 May 2024 | 2024 | Q1 | |
| Q1 2023 | $2,552,000 | +$263,000 | +11% | 01 Jan 2023 | 31 Mar 2023 | 10-Q | 09 May 2024 | 2024 | Q1 | |
| Q1 2022 | $2,289,000 | +$692,000 | +43% | 01 Jan 2022 | 31 Mar 2022 | 10-Q | 11 May 2023 | 2023 | Q1 | |
| Q1 2021 | $1,597,000 | +$611,000 | +62% | 01 Jan 2021 | 31 Mar 2021 | 10-Q | 12 May 2022 | 2022 | Q1 | |
| Q1 2020 | $986,000 | +$232,000 | +31% | 01 Jan 2020 | 31 Mar 2020 | 10-Q | 13 May 2021 | 2021 | Q1 | |
| Q1 2019 | $754,000 | +$243,000 | +48% | 01 Jan 2019 | 31 Mar 2019 | 10-Q | 14 May 2020 | 2020 | Q1 | |
| Q1 2018 | $511,000 | +$459,000 | +883% | 01 Jan 2018 | 31 Mar 2018 | 10-Q | 09 May 2019 | 2019 | Q1 | |
| Q1 2017 | $52,000 | -$655,000 | -93% | 01 Jan 2017 | 31 Mar 2017 | 10-Q | 14 May 2018 | 2018 | Q1 | |
| Q1 2016 | $707,000 | +$556,000 | +368% | 01 Jan 2016 | 31 Mar 2016 | 10-Q | 02 May 2017 | 2017 | Q1 | |
| Q1 2015 | $151,000 | 01 Jan 2015 | 31 Mar 2015 | 10-Q | 03 May 2016 | 2016 | Q1 |
ALPINE IMMUNE SCIENCES, INC. Annual Share-based Payment Arrangement, Noncash Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2023 | $10,630,000 | +$982,000 | +10% | 01 Jan 2023 | 31 Dec 2023 | 10-K | 20 Mar 2024 | 2023 | FY |
| 2022 | $9,648,000 | +$3,408,000 | +55% | 01 Jan 2022 | 31 Dec 2022 | 10-K | 20 Mar 2024 | 2023 | FY |
| 2021 | $6,240,000 | +$2,100,000 | +51% | 01 Jan 2021 | 31 Dec 2021 | 10-K | 20 Mar 2024 | 2023 | FY |
| 2020 | $4,140,000 | +$1,099,000 | +36% | 01 Jan 2020 | 31 Dec 2020 | 10-K | 23 Mar 2023 | 2022 | FY |
| 2019 | $3,041,000 | +$732,000 | +32% | 01 Jan 2019 | 31 Dec 2019 | 10-K | 17 Mar 2022 | 2021 | FY |
| 2018 | $2,309,000 | +$1,471,000 | +176% | 01 Jan 2018 | 31 Dec 2018 | 10-K | 18 Mar 2021 | 2020 | FY |
| 2017 | $838,000 | +$761,000 | +988% | 01 Jan 2017 | 31 Dec 2017 | 10-K | 30 Mar 2020 | 2019 | FY |
| 2016 | $77,000 | +$61,000 | +381% | 01 Jan 2016 | 31 Dec 2016 | 10-K | 18 Mar 2019 | 2018 | FY |
| 2015 | $16,000 | -$54,000 | -77% | 01 Jan 2015 | 31 Dec 2015 | 10-K | 28 Mar 2018 | 2017 | FY |
| 2014 | $70,000 | -$28,000 | -29% | 01 Jan 2014 | 31 Dec 2014 | 10-K | 13 Feb 2017 | 2016 | FY |
| 2013 | $98,000 | 01 Jan 2013 | 31 Dec 2013 | 10-K | 08 Mar 2016 | 2015 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.